Highlights:

• U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS
• Clears the way for entry into the HEALEY ALS Platform Trial expected to commence in Q4 CY2025
• IND supported by robustpreclinical safety data and comprehensive manufacturing and quality information from the previously signed Elanco...